Hers, MD-Led Platform

Hers is the women''s health brand of Hims & Hers Health, Inc., a publicly traded telehealth company (NYSE: HIMS) founded in 2017 and now one of the highest-profile direct-to-consumer telehealth platforms in the United States. Hers covers women''s health conditions across skincare, hair loss, birth control, mental health, and weight loss, and has built GLP-1 prescribing into a central pillar of its product portfolio. The weight loss program follows the consumer telehealth model that Hims & Hers perfected: a low-friction intake questionnaire, a licensed provider review conducted asynchronously, a prescription for compounded or brand-name GLP-1 medication, and home delivery through partner pharmacies. The membership structure — $39 for the first month, $149/month thereafter — bundles platform access and care coordination without separate visit fees. Hers became one of the most prominent voices in the debate over compounded GLP-1 medications during 2024 and 2025, arguing that compounded versions of semaglutide provided critical access for patients who could not afford brand-name drugs. The company pushed back publicly against FDA efforts to restrict compounding, and CEO Andrew Dudum testified that the platform served hundreds of thousands of patients on compounded options. As of early 2026, Hims & Hers entered a partnership with Novo Nordisk to distribute brand-name Wegovy through its platform, expanding options for patients who prefer or require FDA-approved formulations. The Hers GLP-1 program does not include structured behavioral coaching, dietitian support, or a long-term program curriculum — it is a prescription and medication delivery service with app-based progress tracking and provider messaging. This is the right fit for independent, self-directed patients who want modern consumer packaging around their GLP-1 care; it is the wrong fit for patients who need clinical depth, specialty obesity medicine expertise, or comprehensive lifestyle support. Hers operates in most US states and benefits from the infrastructure and provider network of the broader Hims & Hers platform. For women who already use Hers for other health needs, adding GLP-1 weight loss treatment to an existing membership is a natural extension of an established telehealth relationship. Hers covers women''s health conditions across skincare, hair loss, birth control, mental health, and weight loss, and has built GLP-1 prescribing into a central pillar of its product portfolio. The weight loss program follows the consumer telehealth model that Hims & Hers perfected: a low-friction intake questionnaire, a licensed provider review conducted asynchronously, a prescription for compounded or brand-name GLP-1 medication, and home delivery through partner pharmacies. The membership structure — $39 for the first month, $149/month thereafter — bundles platform access and care coordination without separate visit fees. Hers became one of the most prominent voices in the debate over compounded GLP-1 medications during 2024 and 2025, arguing that compounded versions of semaglutide provided critical access for patients who could not afford brand-name drugs. The company pushed back publicly against FDA efforts to restrict compounding, and CEO Andrew Dudum testified that the platform served hundreds of thousands of patients on compounded options. As of early 2026, Hims & Hers entered a partnership with Novo Nordisk to distribute brand-name Wegovy through its platform, expanding options for patients who prefer or require FDA-approved formulations. The Hers GLP-1 program does not include structured behavioral coaching, dietitian support, or a long-term program curriculum — it is a prescription and medication delivery service with app-based progress tracking and provider messaging. This is the right fit for independent, self-directed patients who want modern consumer packaging around their GLP-1 care; it is the wrong fit for patients who need clinical depth, specialty obesity medicine expertise, or comprehensive lifestyle support. Hers operates in most US states and benefits from the infrastructure and provider network of the broader Hims & Hers platform. For women who already use Hers for other health needs, adding GLP-1 weight loss treatment to an existing membership is a natural extension of an established telehealth relationship.